Seres Therapeutics Inc. (NASDAQ:MCRB)

Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
MCRB Weekly Chart

Old Forum Content for MCRB

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: ...
    Now for what's on my radar: $PDSB $PLX $CDTX. Also, $MCRB - watching but still isn't right. (I'm not around today to take any action on any of these.) These are good ones to look into in terms of doing your due diligence. And, yes, if you are buying ...
  • DougL: $MCRB - big call OI - Jun 7.5c - spec play
  • woodman: @steve71 $PLX - I never had any $MCRB, though it's on my radar. I don't have much interest in buying back $CDTX.
  • MongosPawn: $MCRB Bouncing.
  • woodman: $MCRB - @steve71, any thoughts on this one at this juncture. I have no position (and haven't had one at any point) but I'm keeping an eye on this. Seems like everyone expected approval of its antibiotic for C. dif. Post approval, it fell hard. It's now trying to find its sea legs. Institutional ownership remains high, I believe, though I don't know the most recent figures on that (TC2000 says 84%). I'm thinking of buying some at some point down here. Nestle owes it a $125 million up front payment, but it would be cool if Nestle just bought it outright :-)
  • woodman: $MCRB - the product, Vowst, is actually a live microbiome capsule used as a therapy to thwart C. diff recurrence. Insightful article about the product and the relationship with Nestle here: https://www.fiercepharma.com/pharma/fda-approves-first-oral-microbiome-therapy-vowst-will-nestle-be-around-help-seres-launch
  • steve71: $MCRB Not for the fainthearted. I will be out before the close on Weds. Money good so far. $VRTX Biotechs go up and down. Vertex goes up. (There, I've jinxed it.) $XERS Their drug delivery platform is working. Now they just onboard more and more drugs.
  • woodman: @steve71 $MCRB $VRTX $XERS - Nice work with $MCRB.I never got on board though looked at it a lot. $$ tied up elsewhere so I never really got in gear with it. I think your idea to sell before PDUFA is a good one. Seems that approval is very likely, but the stock still isn't moving as hard as one would hope/expect. I get a $CDTX vibe with it (though MCRB does have much greater institutional support than CDTX did/does). I also think there are some questions about rollout post-approval.
  • steve71: @steve71 $MCRB $VRTX $XERS Guess I can only reply to myself, As an only child that's not a problem. I have also seen the JPM concern about slow early sales. That doesn't make sense to me. 20,000 C. diff deaths in U.S. yearly. C. diff is hard to treat initially. Recurrent C. diff is even more difficult, maybe because of drug resistance from the first round. So if recurrence can be 90% prevented why wouldn't the ICU doc treat every single initial case with SER-109? My bet is that every single primary case gets treatment - a run rate of 150,000 to 200,000 yearly in the U.S. alone. So I am hoping for post approval weakness for another bite of the apple.
  • woodman: @steve71 $MCRB $VRTX $XERS - Makes sense. Often the post-approval dips turn out to be great opportunities. CDTX is still suffering from its post-approval migraine. (No position in CDTX currently.)
  • mharps: $MCRB finally a move
  • woodman: $MCRB @steve71 - There you go, buddy. Nice move today as it eyes up PDUFA.
  • steve71: @woodman $MCRB Thanks man. I peeled off a little into the ramp and probably will be out in a week.
  • steve71: $MCRB continues its erratic climb to 4/26 PDUFA
  • steve71: ...
    $MCRB Decision on SER-109 BLA 4/26 ish. C. Diff is hard to treat and very frquently recurs.

    "Background: Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile ...
  • woodman: @steve71 $ARDX $MCRB - MCRB is interesting. I've been looking at it too for a PDUFA run, but I have no position. Are you in?
  • steve71: @steve71 $ARDX $MCRB Couldn't reply to Woodman but I can reply to myself...weird. I do have some MCRB and plan to add. But I may bow out a couple of days before the decision. Hot stove-burned cat investing.
  • woodman: @steve71 $ARDX $MCRB - Thanks, and I agree. If I buy, it would be just for a run into PDUFA, but exit before.
  • mharps: $MCRB up on FDA news have a little
  • mharps: $MCRB $MRSN added but very small bio's seems to be holding up
  • mharps: $MCRB
  • scottto_2: #InsideBarList - My OCD kicked in hard on this one - Thanks Sir @Aragorn - $AAL $AAOI $AAPL $ABC $ABT $ABUS $ACAD $ADI $ADS $AEM $AES $AFL $AGCO $AGIO $AIG $AKAM $AKTX $ALE $ALGT $AMCX $AMN $AMP $AMT $AMZN $AN $ANET $ANGI $ANTM $AON $APA $APD $APRN $ ...
  • DAN: ...
    $MCRB -- Set your alert at $30 bucks. What will you do if that alert is hit? Decide. Alert $30.
    $SQ -- anatomy of a shakeout.
    $NVTA -- Still working on a base...but Friday’s low is a good reference.
    $BIDU -- Still going. Looking for $300
    $ ...
  • Bwhitty: $MCRB volume has started to come in.
  • Bwhitty: $NET $DDOG $MCRB $FSLY selling some partials of my swings into strength.
  • Bwhitty: $MCRB trying to break 33 at recent high this AM.
  • Bwhitty: $MCRB very tight on hourly chart squeezing.
  • Bwhitty: $MCRB held small from the other day. Confirmed breakout.
  • Brett: @Bwhitty $MCRB anytime i see this ticker, i think "McRib". same with $SAIL -- that song... :)
  • Bwhitty: $ROL $$MCRB two that we were watching into the close. 👀 This AM
  • Bwhitty: $MCRB looking frisky at the open.
  • Bwhitty: $MCRB broke down too much for me. Have alert back at HOD
  • Ava: $MCRB trying to breakout of a squeeze, Leif Soreide post on Tweeter
  • Bwhitty: $MCRB mentioned earlier in forum. Tested 9/29 breakout now confirming.
  • Bwhitty: $MCRB I like it here for a decent hold over. Trading politely.
  • Bwhitty: $MCRB small bite into the close.
  • Rasta: $MCRB Do you sell half a Phase3 bio after positive results. Up 350%
  • cgendro1: @Rasta $MCRB With a 400% move, you can bet I'd be selling some! What a gift!
  • Rasta: @cgendro1 $MCRB 570% Halted again
  • Junaid: $MCRB is breaking out of a long squeeze on earnings. Bought in this morning at $11.5 Game plan @Bridget, do you think it will continue over the days to come or should I day trade it?
  • Bridget: @Junaid $MCRB breakouts of low bases are hard to predict. Lots of overhead resistance but new information can cause the stock to recover. This is a highly volatile stock so know that it will likely play with your emotions. Only play this stock with money you are willing to gamble with. I recommend using a 50cent trailing stop and sell if it gets up to $14.
  • Junaid: @Bridget $MCRB Thank you that was very helpful!
  • jdemos: @Junaid $MCRB First of all, I am a novice, so take this thought with a grain of salt. Thought is: Risk of a big gap up overnight is small, so you could sell and be ready to buy back at tomorrow's open if all looks well with same trailing stop. It could settle in a little before filling the gap.
  • spmeyers: @Junaid $MCRB it's a pop on news; tread with care
  • Motorman: @aragorn $MCRB I saw this post a week ago or so and wrote it down. Just checked it again today...would this qualify for a phase 2?
  • Aragorn: @Motorman $MCRB no this was not a volatility squeeze a 6% diff of the top to bottom bollingers. Not a VS. It did fill the gap but below the 8ema today so a bit worrisome
  • Motorman: @Aragorn $MCRB thanks for the analysis.
  • Aragorn: $MCRB starting to fill the gap and AERI making new highs
  • Aragorn: $MCRB moving up above yesterdays outside day
  • Aragorn: $MCRB made a higher low and now looks like it wants to take out he recent high of around 35. A very constructive chart, I picked up a small position once it regained the 8ema at 30.45
  • Bridget: $MCRB going parabolic and breaking above its all time high. Recent ipo. I wouldn't be buying here just yet but I would put this on your watchlist. #ipostrategy
  • woodman: $MCRB - I can't believe this went unmentioned today.
Visit the Trading Forum to join in the discussion.
Stock Price $0.78
Change 3.75%
Volume 3,298,870

Seres Therapeutics Inc is a microbiome therapeutics platform company developing a novel class of biological drugs, which are designed to restore health by repairing the function of a dysbiotic microbiome.

Request Video of MCRB
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!